iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
Vertex to Out-license VX135
  Vertex today announced that it has amended the terms of its agreement with Alios BioPharma regarding the development and commercialization of the nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135. Based on the revised agreement and the rapid changes in the hepatitis C treatment landscape following the introduction of new oral therapies, Vertex plans to out-license VX-135 and to end further investment into research and development efforts in hepatitis C.  
  iconpaperstack View Older Articles   Back to Top   www.natap.org